Abstract: This invention provides: —an aptamer-based electrochemical sensor, wherein said aptamer is covalently bonded to or chemisorbed on an electrode, said aptamer forming a complex with a target molecule and is encapsulated by a gelatin B matrix; —a method of manufacturing said aptamer-based electrochemical sensor; —the use of the aptamer-based electrochemical sensor for the electrochemical determination of a concentration of a target molecule; and —a composite electrode combining a polymeric material and electrically conducting particles for selective analyte detection, wherein said electrode is coated with gelatin type B.

Abstract: The disclosure relates to novel methods for performing a solution based assay reaction with an electroactive active moiety (EAM) that subsequently forms a self-assembled monolayer (SAM) utilizing the advantages of faster solution reaction kinetics, SAM protected electrode and surface based electrochemistry for electronic measurement.

Abstract: Method and arrangement for detecting binding events of molecules, in which, to at least one first molecule which is immobilised on a bioactive surface by a covalent bond, at least one second molecule has been bonded or is bonded, with formation of at least one specific non-covalent bond, the second molecule being bonded or having been bonded chemically covalently to a ligand. The bioactive surface can be contacted with at least one analyte molecule, binding events between the analyte molecule and the ligand being able to be detected by means of an analytical measuring method. The at least one specific non-covalent bond between the first and second molecule is breakable again by supplying a buffer solution. According to the invention, a third molecule is bonded to the second molecule, the third molecule also having a ligand.

Abstract: The present invention relates to an apparatus for detecting compounds, the apparatus having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices.

Abstract: The invention relates to a method for coupling in-line the analysis of molecular interactions by surface plasmon resonance (SPR) with a structural identification by mass spectrometry using the same functionalized support for both types of analysis.

Abstract: Sensing methods are sought to overcome the disadvantages—poor sensitivity and selectivity, poor long-term stability, and undeployable. Sensor of these teachings for detecting and recognizing target molecules includes a layer of molecularly imprinted polymer disposed on a single layer graphene sheet. In some instances, the sensor of these teachings also includes a sensing circuit configured to detect and report impedance changes in a layer of molecularly imprinted polymer disposed on a single layer grapheme sheet, the impedance changes caused by the binding of the target molecules to the molecularly imprinted polymer.

Abstract: The objective of the present invention is to provide a method for simply, inexpensively and accurately assessing, before administering a biological preparation, the therapeutic effect thereof (in particular whether there will be a complete response) or the improvement of symptoms in patients having rheumatoid arthritis. By using at least one serum concentration selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1?, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-?, IFN-?, FGF basic, PDGF-bb sIL-6R and MIP-1?, the therapeutic effect (improvement of symptoms and possibility of response) of an inflammatory cytokine-targeting biological preparation on a patient having rheumatoid arthritis can be predicted in any type of facility in a simple, inexpensive, and highly accurate manner before administering the biological preparation.

Abstract: The method of the invention allows confirmation of infections caused by Streptococcus agalactiae bacterial species. The method employs a specific reaction of immunoreactive proteins obtained from clinical isolates of Streptococcus agalactiae with antibodies present in the serum of patients.

Abstract: Disclosed is a cell wall C-polysaccharide antigen of Streptococcus pneumoniae which contains not more than 10% by weight of protein, and preferably less which has been purified with 0.1N NaOH prior to deproteinizing. Also disclosed are polyvalent antibodies raised against Streptococcus pneumoniae which have been affinity purified by passing them over a chromatographic affinity matrix to which is coupled the purified and at least partially deproteinized antigen to render them antigen-specific.

Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.

Abstract: The present invention provides a detection method using an immunochromatographic test strip that suppresses the occurrence of a so-called white bleaching phenomenon and that is accurate and excellent in sensitivity.

Abstract: A sample analysis device used to detect a level of exposure of organophosphorus within a sample comprising a sample collection pad, at least one conjugate zone comprising an anti-analyte antibody that is conjugated with a reporter label, and a control antibody that is conjugated with a reporter label, a blocking and/or test zone comprising an immobilized nanoparticle or other molecule that captures the Organophosphate-bound analyte, a second blocking and/or test zone comprising an immobilized antibody that binds to the unbound analyte and an optional third blocking and/or control zone comprising an immobilized antibody that binds to the control molecule wherein, when the analyte is bound by the Organophosphate in the sample it will bind to the first test line, and if the analyte is “free’ from the Organophosphate it will bind to the second test line, and the control antibody will bind to the control line.

Abstract: The present disclosure relates to, among other things, systems for detecting the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, lipoprotein or portions thereof and/or PCSK9 unbound lipoproteins present in a biological sample. The present invention also relates to methods of assessing the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, Apo B and/or PCSK9 unbound lipoproteins present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease and monitoring the risk for developing cardiovascular disease.

Abstract: The present invention relates to an anti-lysyl-tRNA synthetase (KRS) antibody selectively binding to KRS, and a use thereof and, more specifically, to an antibody binding to human KRS or a fragment thereof, a method for producing the same, and a composition containing the same for diagnosing cancer, autoimmune diseases or inflammatory diseases. The antibody or fragment thereof of the present invention specifically binds to human KRS, and enables KRS detection and inhibition due to the absence of cross-linkage reactivity with the other proteins including the same ARS family, and thus the antibody or fragment thereof can be used to detect KRS and diagnose KRS-related diseases, i.e., cancer, autoimmune diseases or inflammatory diseases.

Abstract: An in vitro method that allows detection of hepatitis C by detecting hepatitis C virus (HCV) core protein and antibodies to HCV core protein (anti-core antibodies) in a single assay is provided. Cross-reactivity is eliminated in the method preferably by utilizing short peptides, each of which has an amino acid sequence that corresponds to an immunodominant region of the native core protein but which does not wholly encompass the epitope bound by the antibodies utilized in the method. The method can be used to detect the presence of HCV in a subject, and/or to determine the suitability of donor blood or blood products for transfusion purposes. Also provided are diagnostic kits for carrying out the method and a process for selecting suitable capture peptides and monoclonal antibodies for use in the combination method.

Abstract: Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.

Abstract: The present invention relates to the diagnosis of colorectal and ovarian cancers (CRC and OC, respectively). The present invention describes the relationship between endogenous small molecules and CRC or OC. Specifically, the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E isoforms and related metabolites. The present invention also relates to diagnostic markers identified in said method. The present invention relates to the underlying case and pre-symptomatic phases of CRC, the diagnosis of various stages and severity of CRC, the early detection of CRC, monitoring and diagnosing the effect of therapy on CRC and OC health states.

Abstract: The present invention describes a method for predicting a health-state indicative of the presence of ovarian cancer (OC). The method measures the intensities of specific small organic molecules, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to those observed in a population of healthy individuals and/or to the intensities previously observed in a population of confirmed ovarian cancer-positive individuals. Specifically, the present invention relates to the diagnosis of OC through the measurement of vitamin E isoforms and related metabolites. The method enables a practitioner to determine the probability that a screened patient is positive or at risk for ovarian cancer.

Abstract: The present invention provides a composition comprising at least two targeting agents, wherein at least one first targeting agent recognizes a keratin 7 peptide and/or fragment(s) thereof, and at least one second targeting agent recognizes a keratin 19 peptide and/or fragment(s) thereof. Said first and second targeting agents are capable of binding specifically and simultaneously to a heterotypic complex of keratin 7 with keratin 19, and/or fragment(s) thereof. The composition of the invention may be used in methods for diagnosing and/or prognosing, predicting efficacy of treatment, assessing outcome of treatment of assessing recurrence of malignant neoplastic disease, such as e.g. lung cancer, bladder cancer, esophagus cancer, and ovarian cancer in a subject.

Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

Abstract: A cell permeable ATP analog has the following formula: or a physiologically acceptable salt thereof, wherein: R0 is n, o, p are each independently 1, 2, 3, 4, 5, or 6, m is 0, 1, 2, 3, 4, or 5; X is O, S, NH, or CH2. R1 is H or C1-6 alkyl, R2 is H, C1-6 alkyl, C6-30 aryl, C5-32 heteroaryl, or C7-32 alkylaryl; R3, R4 are each independently H, C1-6 alkyl, C6-30 aryl, C5-32 heteroaryl, or C7-32 alkylaryl, wherein R3, and R4 can be combined together to form a ring structure.

Abstract: Embodiments herein provide methods, apparatuses, and systems for detecting, monitoring, measuring, and/or characterizing the activity of phosphoproteins such as tyrosine kinases (TKs) and downstream proteins in TK signal transduction pathways (e.g., TK pathway proteins). In various embodiments, the methods, apparatuses, and systems may use nanoparticles, such as quantum dots (QD), to detect and/or characterize the abnormally overactive TK signaling pathways that underlie tumorgenesis and tumor progression. In various embodiments, the QD-based methods, apparatuses, and systems may have a sufficiently high degree of sensitivity to enable the identification of new TK signaling pathway markers, for example for use in diagnosing, staging, monitoring, and/or prognosing cancers, or in evaluating the efficacy of cancer therapeutics.

Abstract: A method of determining micro-molar concentration of glucose in a body fluid using Surface Enhanced Raman Spectroscopy (SERS), comprising an analyte solution prepared by mixing body fluid and linker molecule solution, allowing the analyte solution to dry on the detection film of the glass substrate; recording and analyzing the glucose specific strong SERS signal in the Raman Spectra; and determining the presence of glucose at micro-molar level by measuring the strong SERS signal.

Abstract: Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of ?-gliadin 33-mer, ?-gliadin-17-mer, ?-gliadin-15-mer, ?-gliadin-17-mer, and glutenin 21-mer.

Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

Abstract: This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications.

Abstract: The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.

Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.

Abstract: Provided is a component measuring apparatus configured to determine a functional form that describes wavelength characteristics of a variation attributable to scattering (S (?)). The apparatus then determines unknown one or more coefficients (p, q) based on a first relational expression that involves a variation attributable to absorption (H (?1)) and a group of second relational expressions that do not involve variations attributable to absorption (H (?2a), H (?2b), H (?2c)). The apparatus then corrects an absorbance measured at an arbitrary wavelength (?) using a function where the one or more coefficients (p, q) are applied to the functional form so as to reduce or eliminate at least the effects of scattering of light.

Abstract: The disclosure provides methods for processing a biological samples and determining the presence or an amount of a polypeptide in a biological sample, such as when the polypeptide is oxytocin or vasopressin.

Abstract: Methods are provided for detecting the amount of one or more HRT panel analytes (i.e., estrone (E1), estrone sulfate (E1s), 17?-estradiol (E2a), 17?-estradiol (E2b), estradiol sulfate (E2s), estriol (E3), equilin (EQ), 17?-dihydroequilin (EQa), 17?-dihydroequilin (EQb), Equilenin (EN), 17?-dihydroequilenin (ENa), 17?-dihydroequilenin (ENb), and ?8,9-dehydroestrone (dE1)) in a sample by mass spectrometry. The methods generally involve ionizing one or more HRT panel analytes in a sample and quantifying the generated ions to determine the amount of one or more HRT panel analytes in the sample. In methods where amounts of multiple HRT panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

Abstract: Example methods and apparatus are disclosed for diagnosing or assisting a diagnosis of a bone tissue condition. A specimen associated with bone tissue suspected of being infected is irradiated using a monochromatic light source. The specimen may be irradiated in vivo or ex vivo, and/or within a growth medium. Light scattered during the irradiation is gathered and its Raman spectral content is determined to detect one or more pathological calcium phosphate minerals, such as brushite and uncarbonated apatite, resulting from a conversion of carbonated-apatite in the presence of bacteria.

Abstract: Some embodiments of a blood coagulation testing system include an analyzer console device and a single-use components configured to releasably install into the console device. In some embodiments, the blood coagulation testing system can operate as an automated thromboelastometry system that is particularly useful, for example, at a point-of-care site. The systems can be configured with features such as individual actuation systems for each measurement module, and firmware for initial and ongoing calibration and error detection.

Abstract: The present invention relates to methods for detecting, diagnosing and/or treating traumatic brain injury by detecting in a biological sample from a patient the levels of one or more of the metabolites: methionine sulfoxide, PC aa C 34:4, ATP, AMP, NAD+, ADP, IMP, spermidine, lysoPC a C20:3, C18:1, and proline. In some embodiments, the method also includes diagnosing the patient with traumatic brain injury when the one or more metabolites in the biological sample is at a different level than a statistically validated threshold for the one or more metabolites, and CT, MRI, or PET indicates traumatic brain injury to the brain of the patient. In further embodiments, once traumatic brain injury is diagnosed, the patient is treated for the traumatic brain injury.

Abstract: Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Abstract: A diagnostic analyzer includes a rotating device, a first optical reader, and a second optical reader. The rotating device includes a first darkened compartment, a second darkened compartment, and an optical path along which the first darkened compartment and the second darkened compartment travel. The first optical reader is operable to read the first darkened compartment and the second optical reader is operable to read the second darkened compartment.

Abstract: A diagnostic analyzer includes a first sample process path, a second sample processing path, and a reaction vessel exchanger device. The first sample process path includes an incubation track operable to move reaction vessels along the first sample process path. The second sample process path includes a processing track, disposed below the first sample process path, which is operable to move reaction vessels along the second sample process path. The reaction vessel exchanger device is configured to transfer the reaction vessels from the first sample processing path to the second sample processing path.

Abstract: A device and method for handling racks of disposable pipette tips in a laboratory automation system are presented. The device comprises a guide rail for guiding racks from a loading region (I) to a supply region (II). The loading region (I) is accessible by a user or a loading device for loading a rack on the guide rail. A plurality of disposable pipette tips stored in a supplying rack located in the supply region (II) is accessible by a delivering device for delivering at least one selected one of the plurality of disposable pipette tips to a pipetting system. The device comprises at least one moveable element, which is controllably moveable by a driving device for selectively enabling or disabling a removal of the supplying rack from the supply region (II). A laboratory automation system comprising such a device and/or for carrying out the method are also presented.

Abstract: Automated fluid handling system comprising a housing and two or more fluid handling units arranged as interchangeable modular components with an external fluidics section and an internal non fluidics section, and wherein the housing comprises a liquid handling panel with two or more of component positions for receiving said interchangeable modular components such that the external fluidics section is separated from the non fluidics section by the liquid handling panel.

Abstract: Systems and methods with the ability to raise the set point temperature immediately after a temperature increase due to radiation exposure, thereby reducing T-dot (rate of change in temperature) errors when trying to cool the inertial system back to its original set point temperature. An example system includes an inertial instrument, a sensor that senses if an increased temperature event has been experienced by the inertial instrument, and a controller device that will increase the set point temperature of the inertial instrument based on the determined increase in temperature. The controller device will also maintain the inertial instrument at a temperature associated with at least one of the sensed increased temperature event or the increased set point temperature.

Abstract: An electromagnetic speedometer for a boat having hull containing an opening includes an electromagnetic coil supported by the hull for establishing an electromagnetic field in the water adjacent the hull opening. A plurality of electrodes are supported by an arrangement that both closes the hull opening and supports the electrodes in engagement with the water adjacent the hull opening. The electrodes are connected by conductors with a velocity measuring circuit arranged above the hull interior surface. Preferably, the electrode support arrangement includes guide tubes supporting the electrodes for removal relative to the boat hull, thereby to permit cleaning of the electrodes. The guide tubes are closed by valves when the electrodes are removed from the assembly. In one embodiment, the electromagnetic coil is of the end-fired type, and in another embodiment, the electromagnetic coil is annular and is arranged above and below the hull.

Abstract: Systems, devices, techniques, and methods are disclosed for an opto-mechanical vibrating beam accelerometer. In one example, a system is configured to couple a laser into optical resonance with opto-mechanically active (OMA) anchors suspending a proof mass; lock frequencies of the laser to optical resonances of the OMA anchors, resulting in a modulated laser coupled with the OMA anchors; demodulate a photocurrent that detects the modulated laser coupled with the OMA anchors to detect at least an amplitude or a phase of the modulated laser; lock a frequency of the modulated laser to dynamically track instantaneous resonance frequencies of mechanical modes of the OMA anchors through changes to the amplitude or phase of the modulated laser induced by coupling of the modulated laser to the OMA anchors; and measure an acceleration based on instantaneous resonance frequencies of the OMA anchors through changes to the amplitude or phase of the modulated laser.

Abstract: A teeter-totter type accelerometer includes one or more platforms configured so as to move in proportion to deformation of the substrate and/or anchor(s). The platform(s) may be in a fixed position relative to the substrate, e.g., by being fixedly attached to the anchor(s) or by being fixedly attached to the substrate, or the platform(s) may be movable relative to the substrate, e.g., by being tethered to the anchor(s) so as to allow the platform(s) to pivot relative to the anchor(s). Electrodes are placed on the substrate underlying the platform(s) for sensing position of the platform(s) relative to the underlying substrate. The teeter-totter proof mass is configured such that it can rotate relative to the platform(s), e.g., by being tethered to the platform(s) or by being tethered to one or more anchors separate from the platform(s). The output of the accelerometer is adjusted based on signals from these platform-sensing electrodes in order to reduce or eliminate offset drift.

Abstract: The present invention relates to A MEMS sensor with movable and fixed components for measuring linear acceleration. The MEMS sensor includes at least two mutually independent differential sensor elements disposed inside a common frame structure providing walls for hermetic sealing of the MEMS sensor. The mutually independent differential sensor elements are pairwise configured to perform double differential detection of linear acceleration. The MEMS sensor includes a common anchoring area to which the at least two differential sensor elements are anchored. The common anchoring area is located at the centroid of the pairwise configured differential sensor elements. A self-test capability of the MEMS sensor is also provided.

Abstract: An electronic device configured for real-time calibration of an on-board accelerometer. A plurality of acceleration measurements are collected from the accelerometer to form a data set. An accelerometer error correction model is maintained that includes bias error calibration parameters, sensitivity calibration parameters, and cross-axis calibration parameters that each specify respective weights for each of bias error, sensitivity error, and cross-axis error. Calibration values are determined for one or more of the bias error calibration parameters, the sensitivity calibration parameters, and the cross-axis error calibration parameters for the data set of acceleration measurements using the accelerometer error correction model. A true acceleration vector may be determined that corresponds to a subsequently received acceleration measurement using the determined calibration values.

Abstract: A measuring method of a scanning probe microscopy moves the probe from the first measuring point to the second measuring point while the probe has contact with the object to be measured and a pressing force weaker than the first pressing force is applied between the probe and the object to be measured after the measurement at the first measuring point has ended, applies the first pressing force between the probe and the object to be measured until the tip end position of the probe reaches the first distance in the depth direction from the upper surface of the object to be measured, and measures the physical property information of the object to be measured after the tip end position of the probe has reached the first distance in the depth direction from the upper surface of the object to be measured at the second measuring point.

Abstract: A semiconductor device manufacturing method which enables high quality semiconductor device testing. The method includes the following steps : providing a test board in which a plurality of IC sockets mounted on the front surface and a plurality of surface mount relay sockets to be electrically coupled to the IC sockets are mounted on the back surface; and placing semiconductor devices in the IC sockets and performing a test on the semiconductor devices with relays attached to the relay sockets. The IC socket and the test board are electrically coupled by a plurality of coupling terminals provided in an area for the IC socket in a plan view, and some of the electronic component sockets are mounted in a manner to overlap some of the IC sockets in a plan view.

Abstract: A structure and method of facilitating testing of an electronic device (device under test or DUT) using a non-permanent and reusable structure to terminate contact pads and contact pin holes on a surface of the DUT.

Abstract: A structure and method of facilitating testing of an electronic device (device under test or DUT) using a non-permanent and reusable structure to terminate contact pads and contact pin holes on a surface of the DUT.

Abstract: A probe card for a testing apparatus of electronic devices comprises at least one testing head which houses a plurality of contact probes, each contact probe having at least one contact tip suitable to abut onto contact pads of a device under test, and a support plate of the testing head associated with a stiffener and an intermediate support, connected to the support plate and suitable to provide a spatial transformation of the distances between contact pads made on the opposite sides thereof. Conveniently, the probe card comprises a support element which is joined to the intermediate support, this support element being made by means of a material having a greater stiffness than the intermediate support, thereby being able to provide local micro rectifications of the intermediate support.